ITG, Inc. has fallen over 50% since its July IPO, driven partly by a large shareholder exit rather than fundamentals. The stock is now valued at 4.9 times its 2027 EBITDA with an estimated 60% upside potential. Despite headline revenue growth of 38%, the company faces challenges including weak organic growth, margin pressure, problematic cash conversion, and high customer concentration with Comcast and Charter making up 53% of Q2 revenue. The large backlog is uncertain due to contract structures, but the recent price drop offers an attractive entry point at depressed multiples.
The story on ITG notes its stock has fallen over 50% since its July IPO, with a valuation at 4.9 times 2027 EBITDA and an estimated 60% upside potential. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 30, 2026 03:02 WIB: out of 150 priced US tech stocks, 63 rose and 87 fell. Notable movers include PANW at USD 392.21 with a 1-day change of +4.66% and Pluang order activity of 43% Sell / 57% Buy, MRVL at USD 263.38 with a 1-day change of +4.56% and Pluang order activity of 62% Sell / 38% Buy, and FIVN at USD 34.17 with a 1-day change of -4.47%.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
